Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep [Internet]. 2020 Dec 1 [cited 2025 Jan 3];10(1). Available from: https://pubmed.ncbi.nlm.nih.gov/32901098/

Yang JJ, Yu D, Wen W, Saito E, Rahman S, Shu XO, et al. Association of Diabetes With All-Cause and Cause-Specific Mortality in Asia: A Pooled Analysis of More Than 1 Million Participants. JAMA Netw Open [Internet]. 2019 Apr 1 [cited 2025 Jan 3];2(4). Available from: https://pubmed.ncbi.nlm.nih.gov/31002328/

Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract [Internet]. 2018 Apr 1 [cited 2025 Jan 3];138:271–81. Available from: https://pubmed.ncbi.nlm.nih.gov/29496507/

Sapra A, Bhandari P. Diabetes. StatPearls [Internet]. 2023 Jun 21 [cited 2024 Oct 23]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK551501/

Kalirai S, Ivanova JI, Perez-Nieves M, Stephenson JJ, Hadjiyianni I, Grabner M, et al. Basal insulin initiation and maintenance in adults with type 2 diabetes mellitus in the United States. Diabetes, Metabolic Syndrome and Obesity [Internet]. 2020 [cited 2024 Oct 21];13:1023–33. Available from: https://www.tandfonline.com/action/journalInformation?journalCode=dmso20

Pourhabibi N, Sadeghi R, Mohebbi B, Shakibazadeh E, Sanjari M, Tol A, et al. Factors affecting nonadherence to treatment among type 2 diabetic patients with limited health literacy: Perspectives of patients, their families, and healthcare providers. J Educ Health Promot [Internet]. 2022 Jan 1 [cited 2024 Oct 22];11(1):388. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9818700/

Ng CJ, Lai PSM, Lee YK, Azmi SA, Teo CH. Barriers and facilitators to starting insulin in patients with type 2 diabetes: A systematic review. Int J Clin Pract. 2015Oct 1;69(10):1050–70.

Article  CAS  PubMed  Google Scholar 

Dalal MR, Grabner M, Bonine N, Stephenson JJ, DiGenio A, Bieszk N. Are patients on basal insulin attaining glycemic targets? Characteristics and goal achievement of patients with type 2 diabetes mellitus treated with basal insulin and physician-perceived barriers to achieving glycemic targets. Diabetes Res Clin Pract. 2016Nov;1(121):17–26.

Article  Google Scholar 

Skriver LKL, Nielsen MW, Walther S, Nørlev JD, Hangaard S. Factors associated with adherence or nonadherence to insulin therapy among adults with type 2 diabetes mellitus: A scoping review. J Diabetes Complications. 2023Oct 1;37(10): 108596

Article  CAS  PubMed  Google Scholar 

Heise T, Chien J, Beals JM, Benson C, Klein O, Moyers JS, et al. Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes. Diabetes Obes Metab [Internet]. 2023 Apr 1 [cited 2024 Nov 26];25(4):1080–90. Available from: https://pubmed.ncbi.nlm.nih.gov/36541037/

Nishimura E, Pridal L, Glendorf T, Hansen BF, Hubálek F, Kjeldsen T, et al. Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing. BMJ Open Diabetes Res Care [Internet]. 2021 Aug 19 [cited 2024 Nov 27];9(1). Available from: https://drc.bmj.com/content/9/1/e002301

Moyers JS, Hansen RJ, Day JW, Dickinson CD, Zhang C, Ruan X, et al. Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein. J Pharmacol Exp Ther [Internet]. 2022 Sep 1 [cited 2024 Nov 26];382(3):346–55. Available from: https://pubmed.ncbi.nlm.nih.gov/35840338/

Bergenstal RM, Weinstock RS, Mathieu C, Onishi Y, Vijayanagaram V, Katz ML, et al. Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial. Lancet [Internet]. 2024 Sep [cited 2024 Nov 10];404(10458). Available from: https://pubmed.ncbi.nlm.nih.gov/39270686/

Bue-Valleskey JM, Kazda CM, Ma C, Chien J, Zhang Q, Chigutsa E, et al. Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial. Diabetes Care [Internet]. 2023 May 1 [cited 2024 Nov 10];46(5):1060–7. Available from: https://doi.org/10.2337/dc22-2396

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int J Surg [Internet]. 2021 Apr 1 [cited 2024 Jun 30];88. Available from: https://pubmed.ncbi.nlm.nih.gov/33789826/

Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev [Internet]. 2019 Oct 3 [cited 2024 Aug 4];10(10):ED000142. Available from: https://pubmed.ncbi.nlm.nih.gov/31643080/

Page MJ, Shamseer L, Tricco AC. Registration of systematic reviews in PROSPERO: 30,000 records and counting. Syst Rev [Internet]. 2018 Feb 20 [cited 2024 May 19];7(1). Available from: https://pubmed.ncbi.nlm.nih.gov/29463298/

Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ [Internet]. 2011 Oct 29 [cited 2025 Feb 5];343(7829). Available from: https://pubmed.ncbi.nlm.nih.gov/22008217/

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ [Internet]. 2003 Sep 6 [cited 2024 Jun 30];327(7414):557–60. Available from: https://pubmed.ncbi.nlm.nih.gov/12958120/

Kazda CM, Bue-Valleskey JM, Chien J, Zhang Q, Chigutsa E, Landschulz W, et al. Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes. Diabetes Care [Internet]. 2023 May 1 [cited 2024 Nov 10];46(5):1052–9. Available from: https://doi.org/10.2337/dc22-2395

Wysham C, Bajaj HS, Prato S Del, Franco DR, Kiyosue A, Dahl D, et al. Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment. New England Journal of Medicine [Internet]. 2024 Sep 10 [cited 2024 Nov 10]; Available from: https://doi.org/10.1056/NEJMoa2403953

Frias J, Chien J, Zhang Q, Chigutsa E, Landschulz W, Syring K, et al. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study. Lancet Diabetes Endocrinol [Internet]. 2023 Mar 1 [cited 2024 Nov 10];11(3):158–68. Available from: https://pubmed.ncbi.nlm.nih.gov/36758572/

Rosenstock J, Juneja R, Beals JM, Moyers JS, Ilag L, McCrimmon RJ. The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa. Endocr Rev [Internet]. 2024 Jun 1 [cited 2024 Nov 26];45(3):379–413. Available from: https://pubmed.ncbi.nlm.nih.gov/38224978/

Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract [Internet]. 2011 Mar [cited 2024 Nov 27];65(3):314–22. Available from: https://pubmed.ncbi.nlm.nih.gov/21314869/

Guerci B, Chanan N, Kaur S, Jasso-Mosqueda JG, Lew E. Lack of treatment persistence and treatment nonadherence as barriers to glycaemic control in patients with type 2 diabetes. Diabetes Therapy [Internet]. 2019 Apr 1 [cited 2024 Nov 27];10(2):437–49. Available from: https://doi.org/10.1007/s13300-019-0590-x

Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence [Internet]. 2016 Jul 22 [cited 2024 Nov 27];10:1299–306. Available from: https://pubmed.ncbi.nlm.nih.gov/27524885/

García-Pérez LE, Álvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. Diabetes Ther [Internet]. 2013 Dec 1 [cited 2024 Nov 27];4(2):175–94. Available from: https://pubmed.ncbi.nlm.nih.gov/23990497/

Edelman S V., Polonsky WH. Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control. Diabetes Care [Internet]. 2017 Nov 1 [cited 2024 Nov 27];40(11):1425–32. Available from: https://pubmed.ncbi.nlm.nih.gov/28801473/

Singh AK, Singh A, Singh R, Misra A. Once-weekly basal insulin icodec: Looking ONWARDS from pharmacology to clinical trials. Diabetes Metab Syndr. 2022Sep 1;16(9): 102615

Article  CAS  PubMed  Google Scholar 

Gentile S, Strollo F, Ceriello A, On behalf of the AMD-OSDI Injection Technique Study Group, Gentile S, Botta A, et al. Lipodystrophy in Insulin-Treated Subjects and Other Injection-Site Skin Reactions: Are We Sure Everything is Clear? Diabetes Ther [Internet]. 2016 Sep 1 [cited 2024 Nov 27];7(3):401–9. Available from: https://pubmed.ncbi.nlm.nih.gov/27456528/

Galdón Sanz-Pastor A, Justel Enríquez A, Sánchez Bao A, Ampudia-Blasco FJ. Current barriers to initiating insulin therapy in individuals with type 2 diabetes. Front Endocrinol (Lausanne). 2024Mar;14(15):1366368

Article  Google Scholar 

Mody R, Huang Q, Yu M, Zhao R, Patel H, Grabner M, et al. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States. Diabetes Obes Metab [Internet]. 2019 Apr 1 [cited 2024 Nov 27];21(4):920–9. Available from: https://pubmed.ncbi.nlm.nih.gov/30520248/

Takase T, Nakamura A, Yamamoto C, Nomoto H, Miya A, Dannoura M, et al. Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial. J Diabetes Investig [Internet]. 2019 May 1 [cited 2024 Nov 27];10(3):699–705. Available from: https://pubmed.ncbi.nlm.nih.gov/30076787/

Polonsky WH, Fisher L, Hessler D, Bruhn D, Best JH. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab [Internet]. 2011 Feb 1 [cited 2024 Nov 27];13(2):144–9. Available from: https://pubmed.ncbi.nlm.nih.gov/21199266/

Jude EB, Malecki MT, Gomez Huelgas R, Prazny M, Snoek F, Tankova T, et al. Expert Panel Guidance and Narrative Review of Treatment Simplification of Complex Insulin Regimens to Improve Outcomes in Type 2 Diabetes. Diabetes Therapy [Internet]. 2022 Apr 1 [cited 2024 Nov 27];13(4):619–34. Available from: https://doi.org/10.1007/s13300-022-01222-2

Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care [Internet]. 1995 [cited 2024 Nov 26];18(2):258–68. Available from: https://pubmed.ncbi.nlm.nih.gov/7729308/

Fowler MJ. Microvascular and Macrovascular Complications of Diabetes. Clinical Diabetes [Internet]. 2011 Jul 1 [cited 2024 Nov 26];29(3):116–22. Available from: https://doi.org/10.2337/diaclin.29.3.116

Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial--revisited. Diabetes [Internet]. 2008 Apr [cited 2024 Nov 26];57(4):995–1001. Available from: https://pubmed.ncbi.nlm.nih.gov/18223010/

Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ [Internet]. 2000 Aug 12 [cited 2024 Nov 26];321(7258):405–12. Available from: https://www.bmj.com/content/321/7258/405

Advani A. Positioning time in range in diabetes management. Diabetologia [Internet]. 2020 Feb 1 [cited 2024 Nov 28];63(2):242–52. Available from: https://pubmed.ncbi.nlm.nih.gov/31701199/

Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, Brown AS, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care [Internet]. 2019 Mar 1 [cited 2024 Nov 28];42(3):400–5. Available from: https://pubmed.ncbi.nlm.nih.gov/30352896/

Gabbay MAL, Rodacki M, Calliari LE, Vianna AGD, Krakauer M, Pinto MS, et al. Time in range: A new parameter to evaluate blood glucose control in patients with diabetes. Diabetol Metab Syndr [Internet]. 2020 Mar 16 [cited 2024 Nov 28];12(1):1–8. Available from: https://doi.org/10.1186/s13098-020-00529-z

Brown A, Guess N, Dornhorst A, Taheri S, Frost G. Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done? Diabetes Obes Metab [Internet]. 2017 Dec 1 [cited 2024 Nov 27];19(12):1655–68. Available from: https://doi.org/10.1111/dom.13009

Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord [Internet]. 2002 [cited 2024 Nov 27];26 Suppl 3:S18–24. Available from: https://pubmed.ncbi.nlm.nih.gov/12174319/

Wallia A, Molitch ME. Insulin Therapy for Type 2 Diabetes Mellitus. JAMA [Internet]. 2014 Jun 11 [cited 2024 Nov 27];311(22):2315–25. Available from: https://jamanetwork.com/journals/jama/fullarticle/1878724